The design and development of a small molecule named
NPB [3-{(4(2,3-dichlorophenyl)piperazin-1-yl}{2-hydroxyphenyl)methyl}-N-cyclopentylbenzamide], which specifically inhibited the phosphorylation of BAD at Ser99 in human
carcinoma cells has been previously reported. Herein, the synthesis, characterization, and effect on
cancer cell viability of
NPB analogs, and the single-crystal X-ray crystallographic studies of an example compound (4r), which was grown via slow-
solvent evaporation technique is reported. Screening for loss of viability in mammary
carcinoma cells revealed that compounds such
as 2[(4(2,3-dichlorophenyl)piperazin-1-yl][naphthalen-1-yl]methyl)
phenol (4e), 5[(4(2,3-dichlorophenyl)piperazin-1-yl][2-hydroxyphenyl)methyl)uran-2-carbaldehyde (4f), 3[(2-hydroxyphenyl][4(p-tolyl)piperazin-1-yl)methyl)
benzaldehyde (4i), and
NPB inhibited the viability of MCF-7 cells with IC50 values of 5.90, 3.11, 7.68, and 6.5 µM, respectively. The loss of cell viability was enhanced by the
NPB analogs synthesized by adding newer rings such as
naphthalene and
furan-2-carbaldehyde in place of N-cyclopentyl-
benzamide of
NPB. Furthermore, these compounds decreased Ser99 phosphorylation of hBAD. Additional in silico density functional theory calculations suggested possibilities for other analogs of
NPB that may be more suitable for further development.